Yang Ge

Yang Ge

Auto-generated profile, based on publicly available information

Yang Ge

Djavad Mowafaghian Centre for Brain Health and Department of Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2023 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
ZZZhiwei Zhang
Zhiwei Zhang
GLGiang N. T. Le
Giang N. T. Le
YGYang Ge
Yang Ge
XTXiaowen Tang
Xiaowen Tang
XCXin Chen
Xin Chen
GWG. Andrew Woolley
G. Andrew Woolley

24 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
BSBryan J. Song
Bryan J. Song
YGYang Ge
Yang Ge
ANAlly Nicolella
Ally Nicolella
MKMin Jee Kwon
Min Jee Kwon
BLBart Lodder
Bart Lodder
MSMorgan Sheng
Morgan Sheng
: Loss-of-function mutations in AKAP11 (a protein kinase A (PKA)-binding protein) greatly increase the risk of bipolar disorder and schizophrenia. To determine the neurobiological functions of AKAP11, we conduct multi-omic and neurobiological analyses of Akap11 mutant mouse brains. We find that AKAP11 is a key regulator of PKA proteostasis in the brain whose loss leads to dramatically increased levels of PKA subunits and phosphorylated PKA substrates, especially in synapses. Akap11 mutant mice show extensive transcriptomic changes throughout the brain, including prominent decreases in synapse-related genes sets. Gene expression is highly impacted in spiny projection neurons of the striatum, a brain region implicated in motivation, cognition and psychotic disorders. Real-time measurements of PKA activity reveal elevated basal PKA activity in the striatum of Akap11 -/- mice, with exaggerated additional response to dopamine receptor antagonists. Behaviorally, Akap11 mutant mice show abnormally prolonged locomotor response to amphetamine, deficits in associative learning and contextual discrimination, as well as depression-like behaviors. Our study connects molecular changes to circuit dysfunction and behavioral disturbance in a genetically valid animal model of psychotic disorder.

9 January 2026 in Science Advances
Verified
Journal Article
Open access
YGYang Ge
Yang Ge
TTTian Tian
Tian Tian
BLBolong Li
Bolong Li
PAPeter Axerio-Cillies
Peter Axerio-Cillies
WCWenlin Chen
Wenlin Chen
YWYu Tian Wang
Yu Tian Wang
The GluN2B subunit of N -methyl- d -aspartate receptors (NMDARs) plays a central role in synaptic development and plasticity, and its hypofunction is linked to autism spectrum disorder (ASD), severe neurodevelopmental delay, and other neuropsychiatric diseases. Therefore, enhancing the function of this NMDAR subunit may provide an effective therapeutic strategy for correcting synaptic and behavioral deficits associated with GluN2B hypofunction. Here, we developed a class of GluN2B-selective positive allosteric modulators and characterized the pharmacological properties and binding site of the lead compound, 175. Systemic application of 175 facilitates hippocampal long-term depression in rats. 175 restores performances in open-field exploration and three-chamber test in Mecp2 overexpression mice that exhibit GluN2B hypofunction and autism-like features. Treatment with 175 also reverses behavioral abnormalities in open-field, Y-maze spontaneous alternation, three-chamber test, and prepulse inhibition in Disc1 mutant mice. Our findings introduce a pharmacological tool for selectively potentiating GluN2B-NMDAR function and highlight its therapeutic potential for cognitive and behavioral symptoms associated with GluN2B hypofunction.